Expert consensus on diagnosis and treatment of SARS-CoV-2 infection in solid organ transplant recipients (2023 edition)

National Medical Center for Infectious Diseases; Branch of Organ Transplantation of Chinese Medical Association; Organ Transplant Rehabilitation Committee of China Association Rehabilitation Medicine; Special Fund for Health Management of Organ Transplant Recipient of China Organ Transplantation Development Foundation

doi:10.3969/j.issn.1674-7445.2023.02.001

Volume 14 Issue 2

Mar. 2023

Turn off MathJax

Article Contents

Article Navigation > ORGAN TRANSPLANTATION > 2023 > 14(2): 163-182

National Medical Center for Infectious Diseases, Branch of Organ Transplantation of Chinese Medical Association, Organ Transplant Rehabilitation Committee of China Association Rehabilitation Medicine, et al. Expert consensus on diagnosis and treatment of SARS-CoV-2 infection in solid organ transplant recipients (2023 edition)[J]. ORGAN TRANSPLANTATION, 2023, 14(2): 163-182. doi: 10.3969/j.issn.1674-7445.2023.02.001

Citation:

PDF( 1393 KB)

Expert consensus on diagnosis and treatment of SARS-CoV-2 infection in solid organ transplant recipients (2023 edition)

doi: 10.3969/j.issn.1674-7445.2023.02.001

Huashan Hospital Affiliated to Fudan University, Shanghai 200040, China

Received Date: 2023-02-11
Available Online: 2023-03-15
Publish Date: 2023-03-15

Abstract

Abstract

Since the end of 2019, the SARS-CoV-2 infection pandemic has swept the world. Although the current SARS-CoV-2 mutants have decreased in pathogenicity and virulence compared with the original strains, and most patients have a good prognosis, the solid organ transplant (SOT) recipients are vulnerable to SARS-CoV-2. And even with vaccination, the risk of hospitalization or death is still high in SOT recipients infected with SARS-CoV-2. What's more, the clinical manifestations, diagnosis and treatment strategy of SOT recipients infected with SARS-CoV-2 has its unique features, which needs high attention. At present, there is a lack of guidelines or consensus in the diagnosis and treatment field of SARS-CoV-2 for such a large number of SOT recipients. Therefore, referring to the "Diagnosis and treatment regimen for SARS-CoV-2 infection (Trial Version 10)" and global published literature, the writing team wrote the "Expert consensus on diagnosis and treatment of SARS-CoV-2 infection in solid organ transplantation recipients (2023 edition)". This consensus was evidence-based written and reached by experts after multiple rounds of discussions, forming 21 recommendations, providing reference for the diagnosis and treatment of SOT recipients infected with SARS-CoV-2.
- Solid organ transplant,
- SARS-CoV-2,
- Diagnosis,
- Treatment

Corresponding authors: Wang Zhengxin, Email: wangzhengxin@huashan.org.cn
Zheng Jianming, Email: zhengjianming@fudan.edu.cn
Chen Jingyu, Email: chenjy@wuxiph.com
Zheng Zhe, Email: zhengzhe@fuwai.com
Huo Feng, Email: gzhuofeng@163.com

FullText(HTML)

References(105)

References

[1]	World Health Organization. WHO Expert Committee on Specifications for Pharmaceutical Preparations[J]. World Health Organ Tech Rep Ser, 2014(986): 1-387, back cover.
[2]	蒋朱明, 詹思延, 贾晓巍, 等. 制订/修订《临床诊疗指南》的基本方法及程序[J]. 中华医学杂志, 2016, 96(4): 250-253. DOI: 10.3760/cma.j.issn.0376-2491.2016.04.004. JIANG ZM, ZHAN SY, JIA XW, et al. Basic methods and procedures for formulating/revising the Clinical Diagnosis and Treatment Guidelines[J]. Natl Med J China, 2016, 96(4): 250-253. DOI: 10.3760/cma.j.issn.0376-2491.2016.04.004.
[3]	BROUWERS MC, KHO ME, BROWMAN GP, et al. AGREE Ⅱ: advancing guideline development, reporting and evaluation in health care[J]. CMAJ, 2010, 182(18): E839-E842. DOI: 10.1503/cmaj.090449.
[4]	CHEN Y, YANG K, MARUŠIC A, et al. A reporting tool for practice guidelines in health care: the RIGHT statement[J]. Ann Intern Med, 2017, 166(2): 128-132. DOI: 10.7326/M16-1565.
[5]	Oxford Centre for Evidence-Based Medicine: levels of evidence (March 2009)[EB/OL]. [2023-02-01]. https://www.cebm.ox.ac.uk/resources/levels-of-evidence/oxford-centre-for-evidence-based-medicine-levels-of-evidence-march-2009.
[6]	LIU H, HE X, WANG Y, et al. Management of COVID-19 in patients after liver transplantation: Beijing working party for liver transplantation[J]. Hepatol Int, 2020, 14(4): 432-436. DOI: 10.1007/s12072-020-10043-z.
[7]	FRASER J, MOUSLEY J, TESTRO A, et al. Clinical presentation, treatment, and mortality rate in liver transplant recipients with coronavirus disease 2019: a systematic review and quantitative analysis[J]. Transplant Proc, 2020, 52(9): 2676-2683. DOI: 10.1016/j.transproceed.2020.07.012.
[8]	WONG GL, WONG VW, THOMPSON A, et al. Management of patients with liver derangement during the COVID-19 pandemic: an Asia-Pacific position statement[J]. Lancet Gastroenterol Hepatol, 2020, 5(8): 776-787. DOI: 10.1016/S2468-1253(20)30190-4.
[9]	MA E, AI J, ZHANG Y, et al. Omicron infections profile and vaccination status among 1881 liver transplant recipients: a multi-centre retrospective cohort[J]. Emerg Microbes Infect, 2022, 11(1): 2636-2644. DOI: 10.1080/22221751.2022.2136535.
[10]	RAJA MA, MENDOZA MA, VILLAVICENCIO A, et al. COVID-19 in solid organ transplant recipients: a systematic review and meta-analysis of current literature[J]. Transplant Rev (Orlando), 2021, 35(1): 100588. DOI: 10.1016/j.trre.2020.100588.
[11]	JAYANT K, RECCIA I, VIRDIS F, et al. COVID-19 in hospitalized liver transplant recipients: an early systematic review and meta-analysis[J]. Clin Transplant, 2021, 35(4): e14246. DOI: 10.1111/ctr.14246.
[12]	DUARSA GWK, SUGIANTO R, YUSARI IGAAA, et al. Predictor factor for worse outcomes in kidney transplant recipients infected with coronavirus disease 2019: a systematic review and meta-analysis[J]. Transpl Immunol, 2023, 76: 101739. DOI: 10.1016/j.trim.2022.101739.
[13]	KULKARNI AV, TEVETHIA HV, PREMKUMAR M, et al. Impact of COVID-19 on liver transplant recipients-a systematic review and meta-analysis[J]. EClinicalMedicine, 2021, 38: 101025. DOI: 10.1016/j.eclinm.2021.101025.
[14]	BANSAL A, KUMAR A, BANSAL RM, et al. The impact of comorbidities on clinical course and outcome, in kidney transplant recipients with COVID-19: a systematic review and analysis[J]. Indian J Transplant, 2020, 14(4): 275. doi: 10.4103/ijot.ijot_79_20
[15]	BARTELT L, VAN DUIN D. An overview of COVID-19 in solid organ transplantation[J]. Clin Microbiol Infect, 2022, 28(6): 779-784. DOI: 10.1016/j.cmi.2022.02.005.
[16]	KREMER D, PIETERS TT, VERHAAR MC, et al. A systematic review and meta-analysis of COVID-19 in kidney transplant recipients: lessons to be learned[J]. Am J Transplant, 2021, 21(12): 3936-3945. DOI: 10.1111/ajt.16742.
[17]	MAHALINGASIVAM V, CRAIK A, TOMLINSON LA, et al. A systematic review of COVID-19 and kidney transplantation[J]. Kidney Int Rep, 2021, 6(1): 24-45. DOI: 10.1016/j.ekir.2020.10.023.
[18]	AN W, WANG Q, KIM TE, et al. Clinical characteristics and outcome of coronavirus disease 2019 infection in patients with solid organ transplants: a systematic review and meta-analysis[J]. J Infect Public Health, 2022, 15(3): 365-372. DOI: 10.1016/j.jiph.2022.02.002.
[19]	HO QY, SULTANA R, LEE TL, et al. Coronavirus disease 2019 in kidney transplant recipients: a systematic review and meta-analysis[J]. Singapore Med J, 2021, DOI: 10.11622/smedj.2021171[Epub ahead of print].
[20]	MOOSAVI SA, MASHHADIAGHA A, MOTAZEDIAN N, et al. COVID-19 clinical manifestations and treatment strategies among solid-organ recipients: a systematic review of cases[J]. Transpl Infect Dis, 2020, 22(6): e13427. DOI: 10.1111/tid.13427.
[21]	DIAZ-AROCUTIPA C, CARVALLO-CASTAÑEDA D, LUIS-YBAÑEZ O, et al. COVID-19 in heart transplant recipients during February-August 2020: a systematic review[J]. Clin Transplant, 2021, 35(9): e14390. DOI: 10.1111/ctr.14390.
[22]	MORRIS S, ANJAN S, PALLIKKUTH S, et al. Reinfection with SARS-CoV-2 in solid-organ transplant recipients: incidence density and convalescent immunity prior to reinfection[J]. Transpl Infect Dis, 2022, 24(3): e13827. DOI: 10.1111/tid.13827.
[23]	VITALE J, MUMOLI N, CLERICI P, et al. Assessment of SARS-CoV-2 reinfection 1 year after primary infection in a population in Lombardy, Italy[J]. JAMA Intern Med, 2021, 181(10): 1407-1408. DOI: 10.1001/jamainternmed.2021.2959.
[24]	MEDIĆ S, ANASTASSOPOULOU C, LOZANOV-CRVENKOVIĆ Z, et al. Risk and severity of SARS-CoV-2 reinfections during 2020-2022 in Vojvodina, Serbia: a population-level observational study[J]. Lancet Reg Health Eur, 2022, 20: 100453. DOI: 10.1016/j.lanepe.2022.100453.
[25]	QURESHI AI, BASKETT WI, HUANG W, et al. Reinfection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in patients undergoing serial laboratory testing[J]. Clin Infect Dis, 2022, 74(2): 294-300. DOI: 10.1093/cid/ciab345.
[26]	中华人民共和国国家卫生健康委员会. 新型冠状病毒感染诊疗方案(试行第十版)[EB/OL]. [2023-01-30]. http://www.nhc.gov.cn/xcs/zhengcwj/202301/32de5b2ff9bf4eaa88e75bdf7223a65a/files/460b0e7b19bd42f3bba00c1efb9b6811.pdf.
[27]	WHO. Public health surveillance for COVID-19: interim guidance, 22 July 2022[EB/OL]. [2023-01-30]. https://apps.who.int/iris/handle/10665/360580.
[28]	中华人民共和国国家卫生健康委员会. 新型冠状病毒肺炎诊疗方案(试行第九版)[EB/OL]. [2023-01-30]. https://www.gov.cn/zhengce/zhengceku/2022-03/15/5679257/files/49854a49c7004f4ea9e622f3f2c568d8.pdf
[29]	WANG W, XU Y, GAO R, et al. Detection of SARS-CoV-2 in different types of clinical specimens[J]. JAMA, 2020, 323(18): 1843-1844. DOI: 10.1001/jama.2020.3786.
[30]	MARJOT T, WEBB GJ, BARRITT AS 4TH, et al. COVID-19 and liver disease: mechanistic and clinical perspectives[J]. Nat Rev Gastroenterol Hepatol, 2021, 18(5): 348-364. DOI: 10.1038/s41575-021-00426-4.
[31]	CHEN Z, XU W, MA W, et al. Clinical laboratory evaluation of COVID-19[J]. Clin Chim Acta, 2021, 519: 172-182. DOI: 10.1016/j.cca.2021.04.022.
[32]	KARAKOYUN I, COLAK A, TURKEN M, et al. Diagnostic utility of C-reactive protein to albumin ratio as an early warning sign in hospitalized severe COVID-19 patients[J]. Int Immunopharmacol, 2021, 91: 107285. DOI: 10.1016/j.intimp.2020.107285.
[33]	LIU X, YUE X, LIU F, et al. Analysis of clinical features and early warning signs in patients with severe COVID-19: a retrospective cohort study[J]. PLoS One, 2020, 15(6): e0235459. DOI: 10.1371/journal.pone.0235459.
[34]	WANG X, CHE Q, JI X, et al. Correlation between lung infection severity and clinical laboratory indicators in patients with COVID-19: a cross-sectional study based on machine learning[J]. BMC Infect Dis, 2021, 21(1): 192. DOI: 10.1186/s12879-021-05839-9.
[35]	GUO J, WANG S, XIA H, et al. Cytokine signature associated with disease severity in COVID-19[J]. Front Immunol, 2021, 12: 681516. DOI: 10.3389/fimmu.2021.681516.
[36]	MITCHELL O, COSAR AM, MALIK MU, et al. Late liver function test abnormalities post-adult liver transplantation: a review of the etiology, investigation, and management[J]. Hepatol Int, 2016, 10(1): 106-114. DOI: 10.1007/s12072-015-9685-2.
[37]	WADEI HM, LEE DD, CROOME KP, et al. Early allograft dysfunction after liver transplantation is associated with short- and long-term kidney function impairment[J]. Am J Transplant, 2016, 16(3): 850-859. DOI: 10.1111/ajt.13527.
[38]	BUCHAN TA, MOAYEDI Y, TRUBY LK, et al. Incidence and impact of primary graft dysfunction in adult heart transplant recipients: a systematic review and meta-analysis[J]. J Heart Lung Transplant, 2021, 40(7): 642-651. DOI: 10.1016/j.healun.2021.03.015.
[39]	SHAH RJ, DIAMOND JM. Primary graft dysfunction (PGD) following lung transplantation[J]. Semin Respir Crit Care Med, 2018, 39(2): 148-154. DOI: 10.1055/s-0037-1615797.
[40]	BHAT KA, MADI D, BHAT S, et al. Profile of secondary bacterial and fungal infections in hospitalized COVID-19 patients in a tertiary care centre[J]. Infect Drug Resist, 2022, 15: 5705-5714. DOI: 10.2147/IDR.S378221.
[41]	PATEL P, DECUIR J, ABRAMS J, et al. Clinical characteristics of multisystem inflammatory syndrome in adults: a systematic review[J]. JAMA Netw Open, 2021, 4(9): e2126456. DOI: 10.1001/jamanetworkopen.2021.26456.
[42]	WEISS-TESSBACH M, RATZINGER F, OBERMUELLER M, et al. Biomarkers for differentiation of coronavirus disease 2019 or extracorporeal membrane oxygenation related inflammation and bacterial/fungal infections in critically ill patients: a prospective observational study[J]. Front Med (Lausanne), 2022, 9: 917606. DOI: 10.3389/fmed.2022.917606.
[43]	NIMMO A, GARDINER D, USHIRO-LUMB I, et al. The GLOBAL IMPact of COVID-19 on solid organ transplantation: two years into a pandemic[J]. Transplantation, 2022, 106(7): 1312-1329. DOI: 10.1097/TP.0000000000004151.
[44]	APASL Covid-19 Task Force, LAU G, SHARMA M. Clinical practice guidance for hepatology and liver transplant providers during the COVID-19 pandemic: APASL expert panel consensus recommendations[J]. Hepatol Int, 2020, 14(4): 415-428. DOI: 10.1007/s12072-020-10054-w.
[45]	GANDOLFINI I, CRESPO M, HELLEMANS R, et al. Issues regarding COVID-19 in kidney transplantation in the ERA of the Omicron variant: a commentary by the ERA Descartes Working Group[J]. Nephrol Dial Transplant, 2022, 37(10): 1824-1829. DOI: 10.1093/ndt/gfac203.
[46]	HAMMOND J, LEISTER-TEBBE H, GARDNER A, et al. Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19[J]. N Engl J Med, 2022, 386(15): 1397-1408. DOI: 10.1056/NEJMoa2118542.
[47]	阿兹夫定片说明书[EB/OL]. [2023-01-30]. https://file.wuxuwang.com/zhuce/ssypfiles/e5d36909ee1240d2e86b0c3a15e0ac29%E8%AF%B4%E6%98%8E%E4%B9%A6.pdf.
[48]	JAYK BERNAL A, GOMES DA SILVA MM, MUSUNGAIE DB, et al. Molnupiravir for oral treatment of COVID-19 in nonhospitalized patients[J]. N Engl J Med, 2022, 386(6): 509-520. DOI: 10.1056/NEJMoa2116044.
[49]	CAO Z, GAO W, BAO H, et al. VV116 versus nirmatrelvir-ritonavir for oral treatment of COVID-19[J]. N Engl J Med, 2023, 388(5): 406-417. DOI: 10.1056/NEJMoa2208822.
[50]	HELLEBERG M, NIEMANN CU, MOESTRUP KS, et al. Persistent COVID-19 in an immunocompromised patient temporarily responsive to two courses of remdesivir therapy[J]. J Infect Dis, 2020, 222(7): 1103-1107. DOI: 10.1093/infdis/jiaa446.
[51]	TROTTIER CA, WONG B, KOHLI R, et al. Dual antiviral therapy for persistent COVID-19 and associated organizing pneumonia in an immunocompromised host[J]. Clin Infect Dis, 2022, DOI: 10.1093/cid/ciac847[Epub ahead of print].
[52]	MARTINEZ MA, CHEN TY, CHOI H, et al. Extended remdesivir infusion for persistent coronavirus disease 2019 infection[J]. Open Forum Infect Dis, 2022, 9(8): ofac382. DOI: 10.1093/ofid/ofac382.
[53]	Dosing & Side Effects. Olumiant® (baricitinib)[EB/OL]. [2023-01-30]. https://www.olumiant.com/dosing-side-effects.
[54]	Tocilizumab (Actemra)[EB/OL]. [2023-01-30]. https://www.rheumatology.org/I-Am-A/Patient-Caregiver/Treatments/Tocilizumab-Actemra.
[55]	YIN S, WANG X, SONG T. Tacrolimus use and COVID-19 infection in patients after solid organ transplantation[J]. Gastroenterology, 2021, 161(2): 728-730. DOI: 10.1053/j.gastro.2021.01.223.
[56]	KOLONKO A, KUCZAJ AA, MUSIALIK J, et al. Clinical insights into the role of immunosuppression in solid organ transplant recipients with COVID-19[J]. Pol Arch Intern Med, 2022, 132(2): 16139. DOI: 10.20452/pamw.16139.
[57]	BELLI LS, FONDEVILA C, CORTESI PA, et al. Protective role of tacrolimus, deleterious role of age and comorbidities in liver transplant recipients with COVID-19: results from the ELITA/ELTR Multi-center European Study[J]. Gastroenterology, 2021, 160(4): 1151-1163. DOI: 10.1053/j.gastro.2020.11.045.
[58]	KARRULI A, SPIEZIA S, BOCCIA F, et al. Effect of immunosuppression maintenance in solid organ transplant recipients with COVID-19: systematic review and meta-analysis[J]. Transpl Infect Dis, 2021, 23(4): e13595. DOI: 10.1111/tid.13595.
[59]	COLMENERO J, RODRÍGUEZ-PERÁLVAREZ M, SALCEDO M, et al. Epidemiological pattern, incidence, and outcomes of COVID-19 in liver transplant patients[J]. J Hepatol, 2021, 74(1): 148-155. DOI: 10.1016/j.jhep.2020.07.040.
[60]	YADAV DK, ADHIKARI VP, LING Q, et al. Immunosuppressants in liver transplant recipients with coronavirus disease 2019: capability or catastrophe?-a systematic review and meta-analysis[J]. Front Med (Lausanne), 2021, 8: 756922. DOI: 10.3389/fmed.2021.756922.
[61]	LEMAITRE F, BUDDE K, VAN GELDER T, et al. Therapeutic drug monitoring and dosage adjustments of immunosuppressive drugs when combined with nirmatrelvir/ritonavir in patients with COVID-19[J]. Ther Drug Monit, 2022, DOI: 10.1097/FTD.0000000000001014[Epub ahead of print].
[62]	LEMAITRE F, GRÉGOIRE M, MONCHAUD C, et al. Management of drug-drug interactions with nirmatrelvir/ritonavir in patients treated for COVID-19: guidelines from the French Society of Pharmacology and Therapeutics (SFPT)[J]. Therapie, 2022, 77(5): 509-521. DOI: 10.1016/j.therap.2022.03.005.
[63]	LANGE NW, SALERNO DM, JENNINGS DL, et al. Nirmatrelvir/ritonavir use: managing clinically significant drug-drug interactions with transplant immunosuppressants[J]. Am J Transplant, 2022, 22(7): 1925-1926. DOI: 10.1111/ajt.16955.
[64]	SALERNO DM, JENNINGS DL, LANGE NW, et al. Early clinical experience with nirmatrelvir/ritonavir for the treatment of COVID-19 in solid organ transplant recipients[J]. Am J Transplant, 2022, 22(8): 2083-2088. DOI: 10.1111/ajt.17027.
[65]	DEVRESSE A, SÉBASTIEN BRIOL, DE GREEF J, et al. Safety, efficacy, and relapse of nirmatrelvir-ritonavir in kidney transplant recipients infected with SARS-CoV-2[J]. Kidney Int Rep, 2022, 7(11): 2356-2363. DOI: 10.1016/j.ekir.2022.08.026.
[66]	LIU Y, LIU B, ZHANG Y, et al. Intestinal absorption mechanisms of 2'-deoxy-2'-β-fluoro-4'-azidocytidine, a cytidine analog for AIDS treatment, and its interaction with P-glycoprotein, multidrug resistance-associated protein 2 and breast cancer resistance protein[J]. Eur J Pharm Sci, 2017, 105: 150-158. DOI: 10.1016/j.ejps.2017.05.009.
[67]	LIU Y, WANG Y, PENG Y, et al. Effects of the antiretroviral drug 2'-deoxy-2'-β-fluoro-4'-azidocytidine (FNC) on P-gp, MRP2 and BCRP expressions and functions[J]. Pharmazie, 2018, 73(9): 503-507. DOI: 10.1691/ph.2018.8555.
[68]	HIRAI T, MIZUTA A, SASAKI T, et al. Drug-drug interaction between remdesivir and immunosuppressant agents in a kidney transplant recipient[J]. Int J Clin Pharmacol Ther, 2022, 60(10): 439-444. DOI: 10.5414/CP204239.
[69]	NAKAMURA J, YANAGIDA M, SAITO K, et al. Epstein-Barr virus encephalitis in a patient with rheumatoid arthritis[J]. Mod Rheumatol Case Rep, 2022, 6(2): 160-162. DOI: 10.1093/mrcr/rxab045.
[70]	SUGAWARA E, MATSUI K, AMASAKI Y. Cytomegalovirus enteritis in a patient with rheumatoid arthritis receiving baricitinib[J]. J Rheumatol, 2020, 47(12): 1835-1836. DOI: 10.3899/jrheum.191395.
[71]	BILALOGLU S, APHINYANAPHONGS Y, JONES S, et al. Thrombosis in hospitalized patients with COVID-19 in a New York City Health System[J]. JAMA, 2020, 324(8): 799-801. DOI: 10.1001/jama.2020.13372.
[72]	MENTER T, HASLBAUER JD, NIENHOLD R, et al. Postmortem examination of COVID-19 patients reveals diffuse alveolar damage with severe capillary congestion and variegated findings in lungs and other organs suggesting vascular dysfunction[J]. Histopathology, 2020, 77(2): 198-209. DOI: 10.1111/his.14134.
[73]	MIDDELDORP S, COPPENS M, VAN HAAPS TF, et al. Incidence of venous thromboembolism in hospitalized patients with COVID-19[J]. J Thromb Haemost, 2020, 18(8): 1995-2002. DOI: 10.1111/jth.14888.
[74]	NICOLAI L, LEUNIG A, BRAMBS S, et al. Immunothrombotic dysregulation in COVID-19 pneumonia is associated with respiratory failure and coagulopathy[J]. Circulation, 2020, 142(12): 1176-1189. DOI: 10.1161/CIRCULATIONAHA.120.048488.
[75]	WICHMANN D, SPERHAKE JP, LÜTGEHETMANN M, et al. Autopsy findings and venous thromboembolism in patients with COVID-19: a prospective cohort study[J]. Ann Intern Med, 2020, 173(4): 268-277. DOI: 10.7326/M20-2003.
[76]	BERLIN DA, GULICK RM, MARTINEZ FJ. Severe COVID-19[J]. N Engl J Med, 2020, 383(25): 2451-2460. DOI: 10.1056/NEJMcp2009575.
[77]	ZHOU F, YU T, DU R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study[J]. Lancet, 2020, 395(10229): 1054-1062. DOI: 10.1016/S0140-6736(20)30566-3.
[78]	CUI S, CHEN S, LI X, et al. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia[J]. J Thromb Haemost, 2020, 18(6): 1421-1424. DOI: 10.1111/jth.14830.
[79]	KLOK FA, KRUIP MJHA, VAN DER MEER NJM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19[J]. Thromb Res, 2020, 191: 145-147. DOI: 10.1016/j.thromres.2020.04.013.
[80]	LODIGIANI C, IAPICHINO G, CARENZO L, et al. Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy[J]. Thromb Res, 2020, 191: 9-14. DOI: 10.1016/j.thromres.2020.04.024.
[81]	NADKARNI GN, LALA A, BAGIELLA E, et al. Anticoagulation, bleeding, mortality, and pathology in hospitalized patients with COVID-19[J]. J Am Coll Cardiol, 2020, 76(16): 1815-1826. DOI: 10.1016/j.jacc.2020.08.041.
[82]	Task Force for the management of COVID-19 of the European Society of Cardiology. ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2-care pathways, treatment, and follow-up[J]. Eur Heart J, 2022, 43(11): 1059-1103. DOI: 10.1093/eurheart/ehab697.
[83]	THACHIL J, TANG N, GANDO S, et al. ISTH interim guidance on recognition and management of coagulopathy in COVID-19[J]. J Thromb Haemost, 2020, 18(5): 1023-1026. DOI: 10.1111/jth.14810.
[84]	BIKDELI B, MADHAVAN MV, JIMENEZ D, et al. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up: JACC State-of-the-Art Review[J]. J Am Coll Cardiol, 2020, 75(23): 2950-2973. DOI: 10.1016/j.jacc.2020.04.031.
[85]	HOY SM. Amubarvimab/romlusevimab: first approval[J]. Drugs, 2022, 82(12): 1327-1331. DOI: 10.1007/s40265-022-01759-3.
[86]	ACTIV-3/Therapeutics for Inpatients with COVID-19 (TICO) Study Group. Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRⅡ-196 plus BRⅡ-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial[J]. Lancet Infect Dis, 2022, 22(5): 622-635. DOI: 10.1016/S1473-3099(21)00751-9.
[87]	中华医学会呼吸病学分会, 中国医师协会呼吸医师分会危重症医学专家组. 奥密克戎变异株所致重症新型冠状病毒感染临床救治专家推荐意见[J]. 中华结核和呼吸杂志, 2023, 46(2): 101-110. DOI: 10.3760/cma.j.cn112147-20221230-00994. Chinese Thoracic Society Critical Care Group, Chinese Association of Chest Physicians Critical Care Group. Expert consensus on treatment of severe COVID-19 caused by Omicron variants[J]. Chin J Tuberc Respir Dis, 2023, 46(2): 101-110. DOI: 10.3760/cma.j.cn112147-20221230-00994.
[88]	SIEMIENIUK RAC, CHU DK, KIM LH, et al. Oxygen therapy for acutely ill medical patients: a clinical practice guideline[J]. BMJ, 2018, 363: k4169. DOI: 10.1136/bmj.k4169.
[89]	NEVERMANN N, WIERING L, WU H, et al. Transplantation programs facing lack of empirical evidence on SARS-CoV-2 vaccination: a society recommendation consensus update[J]. Transpl Infect Dis, 2021, 23(4): e13696. DOI: 10.1111/tid.13696.
[90]	COVID-19 treatment guidelines[EB/OL]. [2023-01-30]. https://www.covid19treatmentguidelines.nih.gov/special-populations/transplant/.
[91]	ROSS LF, OPEL DJ. The case against COVID-19 vaccine mandates in pediatric solid organ transplantation[J]. Pediatr Transplant, 2022, 26(7): e14243. DOI: 10.1111/petr.14243.
[92]	Who needs an additional dose of COVID-19 vaccines?[EB/OL]. [2023-01-30]. https://www.who.int/news-room/questions-and-answers/item/coronavirus-disease-(covid-19)-vaccines.
[93]	中华人民共和国国家卫生健康委员会. 新冠病毒疫苗接种技术指南(第一版)[EB/OL]. [2023-01-30]. http://www.nhc.gov.cn/xcs/gzzcwj/202103/c2febfd04fc5498f916b1be080905771.shtml.
[94]	COHEN MS, NIRULA A, MULLIGAN MJ, et al. Effect of bamlanivimab vs placebo on incidence of COVID-19 among residents and staff of skilled nursing and assisted living facilities: a randomized clinical trial[J]. JAMA, 2021, 326(1): 46-55. DOI: 10.1001/jama.2021.8828.
[95]	LEVIN MJ, USTIANOWSKI A, DE WIT S, et al. Intramuscular AZD7442 (tixagevimab-cilgavimab) for prevention of COVID-19[J]. N Engl J Med, 2022, 386(23): 2188-2200. DOI: 10.1056/NEJMoa2116620.
[96]	SHIELDS AM, BURNS SO, SAVIC S, et al. COVID-19 in patients with primary and secondary immunodeficiency: the United Kingdom experience[J]. J Allergy Clin Immunol, 2021, 147(3): 870-875. DOI: 10.1016/j.jaci.2020.12.620.
[97]	CALABRESE C, KIRCHNER E, VILLA-FORTE A, et al. Early experience with tixagevimab/cilgavimab pre-exposure prophylaxis in patients with immune-mediated inflammatory disease undergoing B cell depleting therapy and those with inborn errors of humoral immunity[J]. RMD Open, 2022, 8(2): e002557. DOI: 10.1136/rmdopen-2022-002557.
[98]	RITSCHL PV, NEVERMANN N, WIERING L, et al. Solid organ transplantation programs facing lack of empiric evidence in the COVID-19 pandemic: a by-proxy society recommendation consensus approach[J]. Am J Transplant, 2020, 20(7): 1826-1836. DOI: 10.1111/ajt.15933.
[99]	COVID 19 rapid guideline: renal transplantation[EB/OL]. [2023-01-30]. https://www.ncbi.nlm.nih.gov/books/NBK566060/pdf/Bookshelf_NBK566060.pdf.
[100]	KUTE VB, GULERIA S, BHALLA AK, et al. ISOT consensus statement for the kidney transplant recipient and living donor with a previous diagnosis of COVID-19[J]. Indian J Nephrol, 2022, 32(4): 288-290. DOI: 10.4103/ijn.ijn_120_21.
[101]	KULKARNI AV, PARTHASARATHY K, KUMAR P, et al. Early liver transplantation after COVID-19 infection: the first report[J]. Am J Transplant, 2021, 21(6): 2279-2284. DOI: 10.1111/ajt.16509.
[102]	GUT G, GÓRAL A, DAL CANTON Z, et al. Kidney Transplantation in COVID pandemic-a review of guidelines[J]. J Clin Med, 2021, 10(13): 2877. DOI: 10.3390/jcm10132877.
[103]	MAHAJAN S, KOHLI HS, GUPTA KL, et al. Infection prevention and control guidelines for COVID[J]. Indian J Nephrol, 2020, 30(3): 185-187. DOI: 10.4103/ijn.IJN_165_20.
[104]	BIANCONE L, MINETTI E, DE ROSA P, et al. Telemedicine monitoring in the follow-up of kidney transplant recipients: consensus indications from an Italian panel of surgeons and nephrologists after the COVID-19 experience[J]. J Nephrol, 2022, 35(3): 725-733. DOI: 10.1007/s40620-021-01193-w.
[105]	SEVER MS, VANHOLDER R, ONISCU G, et al. Kidney transplantation during mass disasters - from COVID-19 to other catastrophes a consensus statement by the DESCARTES Working Group and Ethics Committee of the ERA[J]. Nephrol Dial Transplant, 2022, DOI: 10.1093/ndt/gfac251[Epub ahead of print].

Relative Articles

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(1) / Tables(4)

Get Citation

PDF

XML

Article Metrics

Article views (1363) PDF downloads(296)

Expert consensus on diagnosis and treatment of SARS-CoV-2 infection in solid organ transplant recipients (2023 edition)

doi: 10.3969/j.issn.1674-7445.2023.02.001

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Expert consensus on diagnosis and treatment of SARS-CoV-2 infection in solid organ transplant recipients (2023 edition)

doi: 10.3969/j.issn.1674-7445.2023.02.001

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Export File

Citation

Format

Content